Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
HIV Res Clin Pract ; 20(4-5): 123-129, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-32013805

RESUMO

Background: Chronic HIV is associated with increased inflammation and tissue fibrosis despite suppressive antiretroviral therapy (ART). Monocytes and macrophages have been implicated in the pathogenesis of fibrosis, facilitated by chemokine receptor interactions.Methods: We assessed systemic fibrotic biomarkers (transforming growth factor beta-1 [TGF-ß1], thrombospondin-1 [TSP-1], C-terminal pro-peptide of collagen type I [CICP], and IL-11) in banked plasma from a previously published 24-week open-label trial of cenicriviroc (CVC), a dual CCR2/CCR5 antagonist, among persons living with HIV (PLWH) on stable ART with undetectable plasma HIV RNA (<50 copies/mL). Fibrotic markers were assessed by ELISA and Luminex. Untreated HIV-seronegative individuals (n = 6) of similar age and demographics served as a comparator group.Results: Median age of PLWH was 55 years. At baseline, PLWH had higher median TGF-ß1 (2.11 vs 1.62 ng/mL, p = 0.01), TSP-1 (236.74 vs 83.29 ng/mL, p < 0.0001), and CICP (200.46 vs 111.28 ng/mL, p = 0.01), but lower IL-11 (36.00 vs 53.74 pg/mL, p = 0.01) compared to HIV-uninfected individuals. Over 24 weeks, median TGF-ß1 (-0.74 ng/mL, p = 0.006), TSP-1 (-52.12 ng/mL, p < 0.0001), and CICP (-28.12 ng/mL, p < 0.0001) decreased and IL-11 (28.98 pg/mL, p < 0.0001) increased in PLWH. At week 24, TGF-ß1, CICP, and IL-11 were similar between the two groups (p > 0.05), while TSP-1 remained elevated in PLWH (p = 0.009) compared to controls.Conclusions: PLWH had higher levels of the plasma fibrotic markers TGF-ß1, TSP-1, and CICP. After 24 weeks of CVC, fibrotic markers generally returned to levels comparable to HIV-uninfected controls. Dual CCR2 and CCR5 blockade may ameliorate the detrimental fibrotic events that persist in treated HIV.


Assuntos
Biomarcadores/sangue , Antagonistas dos Receptores CCR5/uso terapêutico , Infecções por HIV/tratamento farmacológico , Imidazóis/uso terapêutico , Receptores CCR2/antagonistas & inibidores , Fármacos Anti-HIV/uso terapêutico , Estudos de Coortes , Feminino , Infecções por HIV/sangue , Humanos , Inflamação/sangue , Inflamação/virologia , Macrófagos/imunologia , Masculino , Pessoa de Meia-Idade , Monócitos/imunologia , Sulfóxidos
2.
J Voice ; 9(3): 308-11, 1995 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-8541975

RESUMO

Alternative medicine has begun to receive the attention of the legitimate medical community. Recent evidence reveals that 34% of American adults interviewed reported using at least one unconventional therapy during 1994. A 3-month survey of patient inquiries, conducted at The Voice Center, Beth Israel Hospital, Boston, MA, U.S.A. revealed that 41% of patients made inquiries about the potential use of "unconventional approaches" in the management of their voice disorders. Alternative medicine, while largely unproven for efficacy, represents a rapidly growing approach. The present article defines several alternative medical practices, describes their theories and potential impact on the management of voice disorders, and calls for empirical studies to follow. The alternative practices discussed are limited to behavioral therapies such as massage therapy, creative visualization, Alexander, mindfulness, and mediatation.


Assuntos
Terapias Complementares , Distúrbios da Voz/terapia , Imagem Eidética , Humanos , Laringe , Massagem , Meditação , Postura , Treinamento da Voz
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA